PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor

PD-L1 Targeting Peptide Probe 68Ga-cPP-BCH for PET Imaging of Solid Tumor

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07442292

Enrollment

Registered

2026-03-02

Start date

2026-02-01

Completion date

2027-06-01

Last updated

2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer (NSCLC), Lung Cancer (SCLC), Melanoma Metastatic, Melanoma (Skin Cancer), PD-L1, PET / CT

Brief summary

The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Aged 18-75, male and female, with ECOG score of 0 or 1; 2. Subjects with lung cancer, melanoma, or other solid tumors scheduled for immunotherapy or combined immunotherapy; 3. underwent PD-L1 IHC examination before therapy; 4. The expected survival was more than 26 weeks; 5. Blood routine test, liver and kidney function meet the following standards: blood routine: WBC \>= 4.0 x 10\^9/L or neutrophil \>= 1.5 x 10\^9/:, PLT \>= 100 x 10\^9 / L, Hb \>= 90g / L; Pt or APTT \<= 1.5 upper limit of normal value; liver and kidney function: total bilirubin \<= 1.5 x ULT (upper limit of normal value), ALT / AST \<= 2.5 upper limit of normal value or \<= 5 x ULT (subject with liver metastasis), ALP \<= 2.5 upper limit of normal value (if bone metastasis or liver metastasis exists, ALP \<= 4.5 upper limit of normal value); BUN \<= 1.5 x ULT, SCR \<= 1.5 x ULT; 6. According to RECIST1.1, there was at least one measurable target lesion; 7. Understand and sign informed consent voluntarily with good compliance.

Exclusion criteria

1. The function of liver and kidney was seriously abnormal; 2. Preparation for pregnant, pregnant and lactating women; 3. Inability to lie flat for half an hour; 4. Suffering from claustrophobia or other mental disorders; 5. Other researchers considered it unsuitable to participate in the trial.

Design outcomes

Primary

Measure	Time frame	Description
MPR	3-6 months	major pathological response, in the surgical pathology after neo-adjuvant immunotherapy, the proportion of active tumors was less than 10%.

Secondary

Measure	Time frame	Description
ORR	3-6 months	Overall Response Rate

Contacts

CONTACTHua Zhu, Professor

zhuhuabch@pku.edu.cn+86-010-88196495

Outcome results